News Grifols board backs IPO for US business Spanish plasma medicine specialist Grifols is planning to sell a minority stake in its US business, via an IPO, to help pay down its debt.
R&D Sponsored The importance of time: Grifols seeks biomarkers for early d... Through a pioneering initiative called Chronos-PD, Grifols is partnering with the Michael J.
News Grifols gets $21m award for Parkinson's biomarker hunt Grifols has been awarded a $21m grant from the Michael J Fox Foundation to find plasma biomarkers to predict Parkinson's years before symptoms start.
News Grifols files drug for rare bleeding disorder in the US Grifols has filed for FDA approval of its new drug for bleeding disorder acquired fibrinogen deficiency (AFD), aiming for a first-in-class US launch.
News Grifols slides as Brookfield pulls out of takeover talks Brookfield has said it is withdrawing from negotiations to take over Grifols, sparking a slump in the Spanish pharma group's shares
News Grifols linked to €7bn takeover offer from Brookfield Private equity company Brookfield has reportedly moved closer to taking control of Grifols, after months of disruption at the Spanish pharma company.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
